Status:
RECRUITING
Primary Prevention With the Lifestyle Tool
Lead Sponsor:
Region Skane
Conditions:
Cardiovascular Diseases
Type 2 Diabetes
Eligibility:
All Genders
35+ years
Phase:
NA
Brief Summary
In this study participants will be randomized to use a digital lifestyle tool over three years or to a control group without access to the tool. The investigators will prospectively via clinical regis...
Detailed Description
Cardiovascular disease (CVD) and type 2 diabetes (T2D) remain leading cause of death in most European countries, and new strategies for prevention are urgently needed. Considerable evidence suggest t...
Eligibility Criteria
Inclusion
- informed consent
- Age above 35 years
Exclusion
- type 1 diabetes, MODY or secondary diabetes
- conditions or treatments that in the judgement of the Investigator could affect the study evaluation
- connection with the study team, funders, authorities, universities or other public or private bodies in such a way that specific interests in the study outcomes could be suspected.
Key Trial Info
Start Date :
April 5 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
90000 Patients enrolled
Trial Details
Trial ID
NCT05309850
Start Date
April 5 2022
End Date
December 31 2026
Last Update
July 16 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Skane University Hospital
Malmo, Sweden, 20502